Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its innovative medicines and cell therapy businesses, which will result in the loss of around 300 jobs or ...
Top central banks forge ahead with closely watched cross-border payments testing A group of the world's leading central banks and over 40 major commercial banks are to step up testing of one of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback